Metabiomed
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Metabiomed makes two core medical products: synthetic absorbable sutures, surgical threads that dissolve harmlessly inside the body after healing, and dental materials used to treat and restore teeth while preserving the natural tooth.
Hospitals, surgical teams, and dental clinics worldwide use its products. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company earns roughly half its revenue from dental materials and instruments and most of the remainder from its suture business.
Summary is AI-generated and may contain errors · figures from DART filings
Metabiomed operates through several overseas subsidiaries, including units in China, Vietnam, Germany, and Japan, giving it a direct international distribution footprint rather than relying solely on third-party distributors.
Metabiomed in five facts
What does Metabiomed do?
Metabiomed makes two core medical products: synthetic absorbable sutures, surgical threads that dissolve harmlessly inside the body after healing, and dental materials used to treat and restore teeth while preserving the natural tooth.
Where is Metabiomed listed and in which sector?
Metabiomed (Korean name: 메타바이오메드) trades under KRX code 059210 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Metabiomed?
Its market capitalisation was US$78.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Metabiomed's latest annual revenue and operating profit?
For fiscal year 2025, Metabiomed reported revenue of US$77.7M, operating profit of US$16.2M and net income of US$8.1M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 9.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 2
- Investor relations (IR) meetingSep 14
- Treasury share acquisition: results report
Metabiomed Co., Ltd. acquired 770,000 treasury common shares between May 19 and June 29, 2026 for a total of US$1.94M through NH Investment & Securities, exceeding the originally planned acquisition of 748,129 shares.
Treasury Shares · Jul 3 - [Amended] Cash/in-kind dividend decision
Metabiomed updated its declared cash dividend of US$0.04 per share, equal to about 1.5% of the recent share price.
Dividend · Jun 30 · 2 versions - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jun 11
- [Amended] Material event report (treasury share acquisition)
Metabiomed updated a disclosed plan to buy back its own shares worth US$2.01M, about 3.0% of its market value.
Treasury Shares · May 14 · 2 versions - [Amended] Cash/in-kind dividend decision
Metabiomed updated its declared cash dividend of US$0.07 per share, equal to about 2.1% of the recent share price.
Dividend · Mar 24 · 2 versions - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Metabiomed reported consolidated results for FY2025: revenue of US$68.6M (+9.5% year on year), operating profit of US$14M (+22.3% year on year) and net income of US$6.17M (−58.5% year on year).
Earnings · Mar 16 - Operating results (consolidated) (preliminary) (fair disclosure)
Metabiomed filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$17.5M (+13.8% year on year), operating profit of US$1.72M (−46.7% year on year) and net income of US$32.6K (−99.5% year on year).
Earnings · Mar 16 - Treasury share disposal: results reportTreasury Shares · Feb 3
- Material event report (treasury share disposal)Treasury Shares · Jan 26